18 Januar 2023 01:08 PM Eastern Daylight Time

BUSINESS WIRE

RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial

In voller Größe anschauen

Opens in new window

Download-Formate

Volle Größe JPEG, 8192x2125, 3.6 MB
Klein JPEG, 480x125, 37.9 KB
Vorschau im JPEG-Format JPEG, 144x37, 9.7 KB
Kleinbild im JPEG-Format JPEG, 120x31, 7.1 KB

Smart Multimedia-Galerie

Prior studies have demonstrated that TETRANITE® is replaced with bone via substitution as it dissolves, stimulating osteoblast cells to produce osteoid (bone precursor) which is then mineralized during the process of bone maturation. (Graphic: Business Wire)

Prior studies have demonstrated that TETRANITE® is replaced with bone via substitution as it dissolves, stimulating osteoblast cells to produce osteoid (bone precursor) which is then mineralized during the process of bone maturation. (Graphic: Business Wire)

View and Share Foto

http://www.businesswire.de/multimedia/de/20230117006135/en/5373543/RevBio-Receives-Approval-to-Start-a-Dental-Clinical-Trial-in-Italy-for-its-Regenerative-Biomaterial

Share

E-Mail

Alle Nachrichten | Nachrichten mit Fotos & Multimedia > Pressemitteilung: RevBio Receives Approval to Start a Dental Clin...

Weitere Business Wire-Websites